Journal of Intensive Care Medicine

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giles, J. T.
Right arrow Articles by Bathon, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giles, J. T.
Right arrow Articles by Bathon, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Intensive Care Medicine, Vol. 19, No. 6, 320-334 (2004)
DOI: 10.1177/0885066604267854
© 2004 SAGE Publications

Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases

Jon T. Giles, MD

Joan M. Bathon, MD

5501 Hopkins Bayview Circle, Rm. 1B.13, Baltimore, MD 21224jbathon{at}jhmi.edu

The ability to target and neutralize macrophage-derived inflammatory cytokines, particularly tumor necrosis factor–{alpha} (TNF-{alpha}), has emerged in recent years as one of the most important advances in the treatment of rheumatoid arthritis, Crohn’s disease, and several other systemic inflammatory diseases. In rheumatoid arthritis, for example, these biological agents rapidly reduce signs and symptoms of joint inflammation and profoundly slow the progression of joint damage. However, data that have emerged following Food and Drug Administration approval of these agents have alerted clinicians to an increased likelihood of opportunistic infections in patients treated with these agents, particularly tuberculosis. The effect of TNF inhibition on the frequency of infection with more common bacterial pathogens is less clear. Animal models of tuberculosis and other opportunistic infections have demonstrated the importance of TNF-{alpha} in controlling and containing intracellular pathogens. The spectrum of infections reported to date in the setting of anti-TNF-{alpha} treatment is reviewed here. In addition, relevant animal data illustrating potential mechanistic roles for TNF-{alpha} in host responses to infection are also reviewed.

Key Words: TNF • infection • tuberculosis • histoplasmosis • rheumatoid arthritis • etanercept • infliximab • adalimumab


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 GutHome page
N Viget, G Vernier-Massouille, D Salmon-Ceron, Y Yazdanpanah, and J-F Colombel
Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis
Gut, April 1, 2008; 57(4): 549 - 558.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
S. M. Newton, S. L. Mackie, A. R. Martineau, K. A. Wilkinson, B. Kampmann, C. Fisher, S. Dutta, M. Levin, R. J. Wilkinson, and G. Pasvol
Reduction of Chemokine Secretion in Response to Mycobacteria in Infliximab-Treated Patients
Clin. Vaccine Immunol., March 1, 2008; 15(3): 506 - 512.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Levine, S. Paczesny, S. Mineishi, T. Braun, S. W. Choi, R. J. Hutchinson, D. Jones, Y. Khaled, C. L. Kitko, D. Bickley, et al.
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
Blood, February 15, 2008; 111(4): 2470 - 2475.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
K.-H. Lee, S. S. Park, I. Kim, J. H. Kim, E. K. Ra, S.-S. Yoon, Y.-C. Hong, S. Park, and B. K. Kim
P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation
Haematologica, May 1, 2007; 92(5): 651 - 657.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J. Franklin, M. Lunt, D. Bunn, D. Symmons, and A. Silman
Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis
Ann Rheum Dis, March 1, 2007; 66(3): 308 - 312.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Heninger, L. H. Hogan, J. Karman, S. Macvilay, B. Hill, J. P. Woods, and M. Sandor
Characterization of the Histoplasma capsulatum-Induced Granuloma.
J. Immunol., September 1, 2006; 177(5): 3303 - 3313.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. L. Allen and G. S. Deepe Jr.
B Cells and CD4-CD8- T Cells Are Key Regulators of the Severity of Reactivation Histoplasmosis
J. Immunol., August 1, 2006; 177(3): 1763 - 1771.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
C Oliveri, R Polosa, S T Holgate, P H Haworth, K S Babu, and H S Arshad
Etanercept in chronic severe asthma * Authors' reply.
Thorax, July 1, 2006; 61(7): 640 - 640.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
G. Stratakos, I. Kalomenidis, V. Papas, K. Malagari, A. Kollintza, C. Roussos, M. Anagnostopoulou, O. Paniara, S. Zakynthinos, and S. A. Papiris
Cough and fever in a female with Crohn's disease receiving infliximab
Eur. Respir. J., August 1, 2005; 26(2): 354 - 357.
[Full Text] [PDF]